Arca
Skip to content
Tools
Tools

Focal segmental glomerulosclerosis (FSGS)

Drug research and approvals for focal segmental glomerulosclerosis (FSGS): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 31 studies of focal segmental glomerulosclerosis (FSGS) are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 31
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 31 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 7

Phase 2 12 of 21

Phase 1 or earlier 4

How its trials ended

87 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 23 whose ending is known, 26% met their primary endpoint, 17% missed it and 57% stopped early.

  • Completed, result not reported3237%
  • Ongoing2832%
  • Met its primary endpoint67%
  • Stopped: other or unclear67%
  • Missed its primary endpoint45%
  • Status unknown45%
  • Stopped: enrollment or feasibility33%
  • Stopped: lack of efficacy22%
  • Stopped: sponsor or business decision22%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 5, 2025A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor bi 764198 taken over a 104 week…BI 764198Boehringer Ingelheim (Canada) Ltd LteeOngoing
Sep 26, 2024A parallel-group treatment, phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of…Frexalimab (SAR441344) / Rilzabrutinib (SAR444671) / Brivekimig (SAR442970)Sanofi-Aventis Canada IncOngoing
Mar 26, 2020An open label, intra-subject dose escalation study of CCX140 b in subjects with primary focal segmental glomerulosclerosis (FSGS) and nephrotic syndromeCCX140-BAmgenPending
Jun 19, 2018A randomized, multicenter, double-blind, parallel, active-control study of the effects of sparsentan, a dual endothelin receptor and angiotensin receptor…Sparsentan (RE-021)Travere TherapeuticsClosed
Apr 17, 2018A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the safety and efficacy of CCX140-b in subjects with focal segmental…CCX140-BAmgenClosed
Feb 13, 2018An adaptive, phase 2 trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-0670512 following multiple injections in adult subjects…PF-06730512PfizerOngoing
Jun 29, 2017A phase 2a, randomized, open-label, active control, multi-center study to assess the efficacy and safety of bleselumab in preventing the recurrence of focal…ASKP1240 (bleselumab)Astellas PharmaClosed
Apr 12, 2017Treatment of proteinuria due to treatment resistant or treatment intolerant idiopathic focal segmental glomerulosclerosis: a 2-part prospective study of h.p.…H.p. acthar gelMallinckrodtClosed
Nov 13, 2013Study of losmapimod to reduce proteinuria in corticosteroid or calcineurin inhibitor resistant idiopathic focal segmental glomerulosclerosis (FSGS)Losmapimod (GW856553)GSKOngoing

FDA orphan designations

Approved first, then open designations, newest first
Apr 13, 2026FilspariTo reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without…Travere Therapeutics, Inc.Approved
Sep 12, 20184-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbo…Treatment of focal segmental glomerulosclerosisChemoCentryx, Inc.Designated
Dec 9, 2015Propagermanium and irbesartanTreatment of focal segmental glomerulosclerosis.Dimerix Bioscience Ltd.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.